FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126359017> ?p ?o ?g. }

• W2126359017 endingPage "2142" @default.
• W2126359017 startingPage "2137" @default.
• W2126359017 abstract "HomeCirculationVol. 106, No. 16New Perspectives on Atherogenesis Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBNew Perspectives on AtherogenesisRole of Abnormal Triglyceride-Rich Lipoprotein Metabolism Henry N. Ginsberg, MD Henry N. GinsbergHenry N. Ginsberg From the Columbia University College of Physicians and Surgeons, New York, NY. Search for more papers by this author Originally published15 Oct 2002https://doi.org/10.1161/01.CIR.0000035280.64322.31Circulation. 2002;106:2137–2142Atherosclerosis, along with the resultant coronary artery disease (CAD), is a leading cause of mortality in industrialized countries. Significant attention has focused on the role of low-density lipoprotein (LDL) in the pathogenesis of CAD. A dyslipidemia characterized by a combination of abnormalities in the plasma levels of triglycerides and high-density lipoprotein (HDL) cholesterol, with or without elevated LDL cholesterol levels, affects many persons with premature CAD, however. In particular, both qualitative and quantitative abnormalities in circulating triglyceride-rich lipoproteins (TRLPs) may be a key factor in the development of CAD.1A number of advances have led to an increased appreciation of TRLP concentrations as independent predictors of risk for CAD. First, the meta-analysis by Hokanson and Austin2 demonstrated that increases in plasma triglyceride levels were associated with increased risk for CAD events, even after adjusting for numerous other predictive factors. The meta-analysis was supported by a more recent prospective study by Jeppesen et al,3 which demonstrated that triglyceride levels were independent predictors of ischemic heart disease in men. Second, a number of studies have demonstrated that TRLPs, whether assembled in and secreted from the intestine or the liver, can penetrate the artery wall and initiate or aggravate atherogenesis. Third, during the last decade, we have gained a much more detailed understanding of the metabolic relationship between high levels of TRLPs, low levels of high-density lipoprotein (HDL) cholesterol, and an abnormally small, cholesterol-depleted, dense LDL.4 This review will attempt to bring together information from recent cellular, biochemical, physiological, and molecular studies to provide an update of our understanding of both normal and abnormal TRLP metabolism and of the atherogenicity of TRLPs.Normal TRLP MetabolismPhysical and Chemical Characteristics of TRLPsAll lipoproteins are macromolecular complexes composed of hundreds to thousands of core lipid molecules (triglycerides and cholesteryl esters) that are covered by a surface monolayer of phospholipids, a small quantity of free cholesterol, and one or more apolipoproteins.5 The apolipoproteins play minor roles as amphipathic proteins at the interface of the aqueous plasma and the lipid-soluble core of each lipoprotein particle. They play major roles as regulators of the lipoprotein metabolism, however.Apolipoprotein (apo) B48, which is synthesized in the intestine only, and apoB100, which is made in the liver, are the necessary structural proteins required for the assembly and secretion of chylomicrons and very low-density lipoproteins (VLDLs), respectively. In the absence of apoB, neither chylomicrons nor VLDLs are made and secreted. In addition, apoB100 is a ligand for the LDL receptor. ApoC-I, apoC-II, and apoC-III, which are synthesized mainly in the liver, are involved in several stages of the intravascular metabolism of TRLP.6,7 ApoC-III is the most abundant apolipoprotein in TRLPs. ApoE is, like apoB100, a ligand for the LDL receptor, and it is also the ligand for the LDL receptor-related protein (LRP), the VLDL receptor, and recently identified apoE receptors.8Alaupovic and colleagues9 developed the concept that apolipoprotein specificity can define subclasses of lipoproteins beyond the basic separation into those containing apoB and those containing apoA-I. Heterogeneity of the TRLPs based on apolipoprotein composition has been demonstrated by numerous laboratories, with particles carrying or lacking apoE, apoC-II, and apoC-III isolated by immunologic methods. Tomiyasu and coworkers10 have reported that the presence or absence of these apolipoproteins can impact the metabolism of apoB, the latter being a marker of the entire lipoprotein particle. The physiological determinants of the specific apolipoprotein content of any TRLP are undefined, although size and lipid composition seem to play important roles. It is also not clear whether apoB-containing lipoproteins are secreted with proportions different from those of other apolipoproteins, or if the apolipoprotein-specific subclasses are created entirely in plasma.Regulation of TRLP Assembly and SecretionPlasma levels of TRLP are determined by rates of secretion from the intestines and liver, as well as by rates of catabolism. The latter process includes both triglyceride hydrolysis and particle uptake by cells. Excellent reviews on the assembly and secretion of both intestinal11 and hepatic12,13 TRLP have been published recently, so only a brief description will be provided here. It seems that both apoB48 in the intestine and apoB100 in the liver are constitutively synthesized, and that their secretion is regulated mainly by the availability of the core lipids (triglycerides and cholesteryl esters) that they deliver into the circulation. The assembly of chylomicrons is stimulated by the delivery of dietary lipids into the cells of the small intestinal villi. Both lipogenesis and the delivery of fatty acids (from either peripheral lipolysis of stored adipose tissue triglyceride or as components of TRLP remnant core lipids) can stimulate the assembly of VLDL in the liver. Microsomal triglyceride transfer protein (MTP)14 plays a critical role in the transfer of lipoprotein lipids from the cytosol and/or endoplasmic reticulum membrane to nascent apoB. Indeed, absence of MTP results in the syndrome of abetalipoproteinemia and the absence of apoB lipoproteins. Recent studies indicating regulation of MTP gene expression by insulin, possibly via the transcriptional activity of sterol response element binding protein 1c (SREBP1c), suggests a molecular basis for the link between insulin resistance and increased VLDL secretion.15 Also of note, a series of recent studies in cultured liver cells and in transgenic animals indicates that the level of apoE in the hepatocytes impacts the assembly and secretion of TRLP.16,17Regulation of TRLP CatabolismCatabolism of TRLPs begins with hydrolysis of core triglyceride by the enzyme lipoprotein lipase (LpL). LpL-mediated lipolysis is modulated by the relative amounts of apoC-II and apoC-III on the TRLPs.18 LpL is synthesized in fat and muscle and is secreted into the interstitial space. After secretion, LpL binds to glycosaminoglycans on the interstitial side of endothelial cells and then, via undefined pathways, undergoes transcytosis to the luminal surface of the capillary endothelium, where it is bound to heparan sulfate proteoglycans. It is LpL bound on the surface of vascular endothelial cells that interacts with TRLPs. ApoC-II is the necessary activator of LpL, and, although complete deficiency of apoC-II is extremely rare, heterozygotes for mutations in the apoC-II gene may have modest elevations in plasma TRLP levels. ApoC-III is an inhibitor of LpL, possibly by interfering with the binding of chylomicrons and VLDL to the heparan sulfate proteoglycans on endothelial cells.6,7 Importantly, persons lacking apoC-III have very low levels of TRLP accompanied by very efficient lipolysis of triglycerides.19 Furthermore, mice in which the apoC-III gene has been deleted also have very low triglyceride levels in blood and very efficient lipolysis of TRLP.20 LpL may also play a role as a bridging molecule and facilitate the uptake of remnant lipoproteins directly into cells.21Lipolysis of TRLP takes place in the capillary beds of adipose tissue, skeletal muscle, and the heart; the smaller chylomicron and VLDL remnants that remain are then able to permeate the fenestrated endothelium separating the hepatocyte surface and the space of Disse from the circulation.22 LDL receptors and the LDL receptor-related protein (LRP) on the surface of hepatocytes clear the remnant lipoproteins via an interaction with apoE on the apoB48-containing chylomicron remnant and with either apoB100 or apoE on VLDL remnants.22,23 Proteoglycans on the cell surface also play an important role in TRLP remnant uptake by the liver.24 Hepatic clearance seems to be the singular final step for chylomicron metabolism, whereas both hepatic clearance and conversion to intermediate-density lipoproteins (IDLs) and LDLs are alternative pathways for VLDL-remnant metabolism.18 Hepatic triglyceride lipase plays an important role in both the uptake and the conversion of TRLP remnants to IDL and LDL. Hepatic lipase seems to act both as a ligand and an enzyme in these processes.25The role of apoE in hepatic uptake of TRLP remnants has been very well studied.22,24,26 ApoE is a ligand for the LDL receptor; this is critical for intestinally derived TRLPs that carry apoB48, which lacks the LDL receptor binding domain present in apoB100. ApoE is also the ligand for LRP and binds to heparan sulfate proteoglycans; the latter seems to enhance interaction between TRLP remnants and LRP. Mice lacking apoE accumulate apoB48 particles and have severe hyperlipidemia and accelerated atherosclerosis. Rare instances of the absence of apoE in humans confirms the findings in mice. Additionally, persons homozygous for apoE2, which is defective in binding to the LDL receptor, are predisposed to develop type III dyslipoproteinemia, in which both intestinal and hepatic TRLP remnants accumulate.The C apolipoproteins play particularly important roles in hepatic uptake of TRLP remnants.6,7 Early studies demonstrated that all 3 of these proteins inhibited the uptake of TRLP by the liver.27,28 In particular, apoC-I plays an inhibitory role in the binding of chylomicrons and VLDL to both the LDL receptor and LRP.29 Transgenic mice overexpressing apoC-I have moderate elevations in both plasma triglyceride and cholesterol levels and accumulate both apoB48- and apoB100-containing lipoproteins.30Abnormal TRLP MetabolismAbnormalities in TRLP Assembly and SecretionIncreased rates of secretion of VLDL triglycerides are characteristic in persons with hypertriglyceridemia. Numerous studies of both VLDL triglycerides and VLDL apoB have indicated that the vast majority of people with elevated levels of VLDL have increased rates of secretion of TRLP into plasma.18,31–35 The most common physiological basis for these abnormalities seems to be insulin resistance, with a combination of increased free fatty acid flux from the periphery and insulin-stimulated lipogenesis driving VLDL production.36 Of interest are recent studies describing a potential link between hyperinsulinemia, SREBP1-c gene expression, lipogenesis, and hyperlipidemia.37,38Increased VLDL secretion also characterizes familial combined hyperlipidemia, a common genetic form of dyslipidemia associated with coronary disease.34,35 Familial combined hyperlipidemia is most likely an oligogenic disorder, but no genetic variations have yet been definitively associated with increased assembly and secretion of VLDL. This is clearly a high priority for many investigative groups.The assembly and secretion of TRLP from the intestine seem to be regulated by delivery of dietary cholesterol and triglycerides. However, recent studies identifying genes related to sterol absorption39,40 and the newly defined role of nuclear receptors LXR and FXR41 in intestinal bile and sterol metabolism suggest that novel insights regarding individual variability in the absorption of dietary sterols or fats, and subsequent chylomicron formation, may be forthcoming in the near future.Abnormalities in TRLP CatabolismThe clearance of TRLP from plasma involves 2 phases; the initial step is lipolysis of nascent chylomicrons and VLDL, which is followed by hepatic uptake of remnants of those particles. In the case of VLDL, conversion to LDL can also occur. Persons lacking LpL enzymatic activity will present with severe hypertriglyceridemia and hyperchylomicronemia. Fortunately, although more than 50 mutations in the gene for LpL that could result in complete loss of activity have been identified, they rarely occur; the prevalence of patients with complete absence of LpL activity is about 1 per million. In contrast, the more common LpL mutations, such as D9N and N291S, result in only partial loss of enzymatic activity. These types of mutations and partial loss of LpL activity are present in about 2% to 5% of the population. Persons who are heterozygous for these mutations have moderate reductions in LpL activity and concomitant modest increases in plasma triglyceride levels, along with low levels of HDL cholesterol.42 In some studies, 43,44 heterozygosity for the more common LpL mutations has been associated with increased risk of atherosclerotic cardiovascular disease. Smoking seems to interact with these mutations to increase risk for CAD.45As mentioned, increased levels of apoC-III would likely inhibit LpL-mediated hydrolysis of chylomicron and VLDL triglycerides. Indeed, although the absence of apoC-III is associated with low levels of plasma TRLP, elevated plasma levels of apoC-III are associated with increased levels of VLDL and decreased fractional catabolism in humans.46 Transgenic mice overexpressing apoC-III have severe hypertriglyceridemia,47 resulting mainly from inhibition of LpL-mediated triglyceride lipolysis.47,48The apoC-III content in plasma parallels the levels of VLDL and HDL. Additionally, because TRLPs can carry greater numbers of apoC-III molecules per particle than HDL particles, increased TRLP levels will lead to increased apoC-III concentrations. This made it difficult to move from the association of high apoC-III levels and increased TRLP to defining an etiologic role for apoC-III in hypertriglyceridemia. Several studies have, however, demonstrated increased rates of secretion of newly synthesized apoC-III into plasma in subjects with hypertriglyceridemia.49–51 These results strongly suggest that increased production of apoC-III could have played a primary, or at least an aggravating, role in the development of hypertriglyceridemia.On the basis of the above facts, many investigators studying abnormalities in TRLP metabolism, particularly familial combined hyperlipidemia, have focused on both the apoC-III gene and the cluster of genes for apoA-I, apoC-III, and apoA-IV on the long arm of chromosome 11.52,53 Indeed, the first genetic polymorphism associated with hyperlipidemia, an SstI restriction enzyme site in the 3′ untranslated region (named the S2 allele),54 remains an important determinant of both hypertriglyceridemia and risk for familial combined hyperlipidemia. Several years ago, a series of polymorphic sites was identified in an insulin response element (IRE) in the apoC-III gene promoter, offering a potential basis for the link between hypertriglyceridemia, familial combined hyperlipidemia, and insulin resistance.55 Recent studies examining that association, however, are contradictory. The strong association of these elements in the apoC-III promoter with the presence of the S2 allele of the apoC-III gene may confound these studies. Other polymorphisms in the apoA-I–apoC-III region, together with the Sst polymorphism, seem to add significantly to the association of the S2 allele with hypertriglyceridemia. Until mechanistic studies define the manner in which these polymorphisms affect apoC-III and triglyceride metabolism, however, the role of these genetic variations will remain unclear.The peroxisome proliferator-activated receptor α (PPAR-α) has been linked to the regulation of apoC-III gene expression, and this may provide a molecular mechanism for the triglyceride-lowering effects of fibrates, which are PPAR-α agonists.56,57 Importantly, PPAR-α agonists repress apoC-III gene expression in rodent livers.58,59 Because apoC-III inhibits LpL-mediated lipolysis of TRLP, suppression of apoC-III synthesis could be a key link between fibrate treatment and improved triglyceride catabolism observed in human studies.60 PPAR-α agonists also enhance fatty acid oxidation in the liver, which subsequently affects triglyceride synthesis and VLDL production.56,57 Thus, PPAR-α agonists could potentially reduce triglyceride levels by both decreasing secretion and accelerating fractional catabolism of VLDL triglycerides.Abnormalities in Hepatic Uptake of TRLP RemnantsRemoval of TRLP remnants by the liver is a complex process, and abnormalities in that process can derive from a number of pathways. Remnant removal can be affected by the ability of LpL, and possibly of hepatic lipase, to initially generate remnants that can be recognized by the liver; by the number and activity of hepatic remnant receptors, such as the LDL receptor and LRP; and by the interaction of TRLP apolipoproteins, particularly apoE and the C apolipoproteins, with hepatic receptors and/or cell surface proteoglycans. We will focus on the latter aspects of remnant removal.As noted in the section on normal TRLP metabolism, apoE plays a key role in particle uptake by the liver.12,18,22,24 There is much less information available regarding the C apolipoproteins and abnormal hepatic uptake of TRLP remnants. As noted earlier, overexpression of apoC-I in mice leads to a pattern consistent with combined hyperlipidemia.30,61 Unexpectedly, the apoC-I–deficient mouse has reduced fractional catabolism of TRLP.62 Thus, the role of apoC-I in human dyslipidemias in which TRLP remnants accumulate is unclear. The potential adverse effects of increased synthesis of apoC-III on TRLP lipolysis were detailed above. Similarly, increased entry into plasma of apoC-III could impair hepatic uptake of TRLP remnants.27,28 The data from transgenic mice overexpressing apoC-III, however, suggest that this apolipoprotein has its major impact via reduced hydrolysis of TRLP triglycerides.47,48Atherogenicity of TRLPsAbnormal transport and metabolism of TRLP, particularly in the postprandial period, have been linked to the presence of atherosclerosis, both in the coronary and carotid arteries.1,63–65 Chylomicrons and their remnants, as well as VLDL remnants, can penetrate into, and be trapped inside, the artery wall, where they can be taken up by macrophages and smooth muscle cells. Animal studies have shown that particle size determines the rate of particle entry into the artery. Both rabbit and mouse models of increased plasma apoB48-TRLP remnants develop atherosclerosis, and those remnants are actively taken up by arteries.66,67 Importantly, TRLPs have also been isolated from human artery segments.68 LpL, which would normally facilitate the catabolism of TRLPs in fat and muscle, may also be pro-atherogenic in the artery wall. Macrophages make LpL, and transgenic mice overexpressing LpL in macrophages have increased atherosclerosis.69 Whether this occurs because LpL increases penetration and retention of TRLP by the artery wall70 or because it facilitates endocytosis of TRLPs into macrophages is unclear.Atherogenicity of TRLP SubclassesThe Cholesterol Lowering Atherosclerosis Study71 demonstrated that increased concentrations of apoC-III in HDL, a surrogate for efficient catabolism of TRLP, were associated with stabilization of atherosclerosis in subjects randomized to colestipol/niacin treatment. The Monitored Atherosclerosis Regression Study72 reported an association between higher apoB:C-III TRLPs and the progression of CAD. Koren et al73 identified a significant positive correlation between the global angiographic score and HDL cholesterol, the ratio of apoC-III in HDL to that in apoB lipoproteins, the total number of apoB-containing lipoproteins, and apoB:C:E lipoprotein levels. Sacks et al, 74 using Cholesterol And Recurrent Events (CARE) trial data, stressed the importance of the number of apoB particles and, in particular, the apoC-III–enriched apoB particles in VLDL and LDL in predicting cardiovascular events.Atherogenicity of TRLPs, Low HDL Cholesterol Levels, and Small, Dense LDLSome of the atherogenicity of TRLPs derives from the nearly universal association of increased VLDL and chylomicron levels with low levels of HDL cholesterol and increased numbers of small, cholesteryl ester-depleted, dense LDL.4 This combination is characteristic of patients with the insulin resistance syndrome36 and strongly predicts an increased risk for CAD. The relative importance of each of these lipoprotein abnormalities as risk factors for CAD is, however, unclear. Although several population studies have suggested that small dense LDL are particularly atherogenic, patients with familial hypercholesterolemia have large, cholesteryl ester-rich LDL and increased CAD. Additionally, in the CARE trial, large LDL predicted CAD events.75Although the increased secretion of TRLP associated with insulin resistance can result in reduced HDL levels and the generation of small dense LDL, impaired TRLP catabolism resulting from reduced LpL activity can also “drive” these changes in HDL and LDL.76 A detailed discussion of the pathophysiological basis for the close association between increased levels of TRLP, reduced HDL cholesterol levels, and small, dense LDL is beyond the scope of this review, but it is also clear that all 3 lipid/lipoprotein abnormalities are closely associated through the action of cholesteryl ester transfer protein.77ConclusionsThe causes of abnormal TRLP metabolism and hypertriglyceridemia are complex and varied. An important unanswered question is whether all forms of hypertriglyceridemia are equally atherogenic. Although it may be concluded from a number of studies in different experimental systems, as well as from naturally occurring extremes such as complete LpL deficiency, that very large, nascent (unmetabolized) TRLPs are less atherogenic than smaller remnant TRLPs, the ability to find some clear cut point between nonatherogenic and atherogenic TRLPs continues to evade us. The question of whether remnant TRLP should be classified as more or less atherogenic on the basis of apoC-III content has been addressed in a number of studies, some of which support such an approach.71–74 To advance from associations to causality, however, will take additional studies focusing on the etiology of increased apoB:C-III particles (increased production versus prolonged plasma residence time) and must be based on evidence for unique atherogenic properties of such TRLP. Until such data are available, it may be best to focus on the development of improved methods for determining the number of apoB-containing lipoprotein particles in the circulation, particularly the number of TRLP remnants, IDL, and LDL particles. Despite the complexity inherent in lipoprotein disorders, the simple message that continues to emerge from all available data is that reducing apoB-containing lipoproteins while increasing apoA-I–containing lipoproteins is beneficial.78FootnotesCorrespondence to Henry N. Ginsberg, MD, Department of Medicine, PH 10-305, Columbia University, 630 West 168th St, New York, NY 10032. E-mail [email protected] References 1 Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to treatment. Am J Cardiol. 2001; 87: 1174–1180.CrossrefMedlineGoogle Scholar2 Hokanson JE, Austin MA. Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996; 3: 213–219.CrossrefMedlineGoogle Scholar3 Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998; 97: 1029–1036.CrossrefMedlineGoogle Scholar4 Krauss RM. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med. 1999; 105: 58S–62S.Google Scholar5 Ginsberg HN. Lipoprotein physiology. In: Hoeg J, ed. Endocrinology and Metabolism Clinics of North America. Philadelphia, Pa: WB Saunders Co; 1998:503–519.Google Scholar6 Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 2001; 12: 297–304.CrossrefMedlineGoogle Scholar7 Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999; 19: 472–484.CrossrefMedlineGoogle Scholar8 Mahley RW, Huang Y, Rall SC. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J Lipid Res. 1999; 40: 1933–1949.CrossrefMedlineGoogle Scholar9 Alaupovic P, Tavella M, Fesmire J. Separation and identification of apo-B-containing lipoprotein particles in normolipidemic subjects and patients with hyperlipoproteinemias. Adv Exp Med Biol. 1987; 210: 7–14.CrossrefMedlineGoogle Scholar10 Tomiyasu K, Walsh BW, Ikewaki K, et al. Differential metabolism of human VLDL according to content of ApoE and ApoC-III. Arterioscler Thromb Vasc Biol. 2001; 21: 1494–500.CrossrefMedlineGoogle Scholar11 Hussain MM. A proposed model for the assembly of chylomicrons. Atherosclerosis. 2000; 148: 1–15.CrossrefMedlineGoogle Scholar12 Ginsberg HN, Goldberg IJ. Regulation of lipoprotein metabolism. In: Jefferson L, Cherrington A, eds.Handbook of Physiology, vol II.The Endocrine Pancreas and the Regulation of Metabolism. New York, NY: Oxford University Press; 2001. In press.Google Scholar13 Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta. 1999; 1440: 1–31.CrossrefMedlineGoogle Scholar14 Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, et al. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu Rev Nutr. 2000; 20: 663–697.CrossrefMedlineGoogle Scholar15 Sato R, Miyamoto W, Inoue J, et al. Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription. J Biol Chem. 1999; 274: 24714–24720.CrossrefMedlineGoogle Scholar16 Mensenkamp AR, Jong MC, van Goor H, et al. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem. 1999; 274: 35711–35718.CrossrefMedlineGoogle Scholar17 Huang Y, Ji ZS, Brecht WJ, et al. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. Arterioscler Thromb Vasc Biol. 1999; 19: 2952–2959.CrossrefMedlineGoogle Scholar18 Ginsberg HN, Dixon JL, Goldberg IJ. VLDL cascade system. In: Betteridge DJ, Illingworth R, Shepherd J, eds. Lipoproteins in Health and Disease. London, UK: Arnold Publishers; 1999:55–70.Google Scholar19 Ginsberg HN, Le N-A, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986; 78: 1287–1295.CrossrefMedlineGoogle Scholar20 Maeda N, Li H, Lee D, et al. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem. 1994; 269: 23610–23616.CrossrefMedlineGoogle Scholar21 Merkel M, Kako Y, Radner H, et al. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: direct evidence that lipoprotein lipase bridging occurs in vivo. Proc Natl Acad Sci U S A. 1998; 95: 13841–13846.CrossrefMedlineGoogle Scholar22 Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997; 38: 2173–2192.CrossrefMedlineGoogle Scholar23 Veniant MM, Zlot CH, Walzem RL, et al. Lipoprotein clearance mechanisms in LDL receptor-deficient “Apo-B48-only” and “Apo-B100-only” mice. J Clin Invest. 1998; 102: 1559–1568.CrossrefMedlineGoogle Scholar24 Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999; 40: 1–16.MedlineGoogle Scholar25 Connelly PW. The role of hepatic lipase in lipoprotein metabolism. Clin Chim Acta. 1999; 286: 243–255.CrossrefMedlineGoogle Scholar26 Rohlmann A, Gotthardt M, Hammer RE, et al. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998; 101: 689–695.CrossrefMedlineGoogle Scholar27 Shelburne F, Hanks J, Meyers W, et al. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest. 1980; 65: 652–658.CrossrefMedlineGoogle Scholar28 Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985; 26: 556–565.CrossrefMedlineGoogle Scholar29 Kowal RC, Herz J, Weisgraber KH, et al. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990; 265: 10771–10" @default.
• W2126359017 created "2016-06-24" @default.
• W2126359017 creator A5007048045 @default.
• W2126359017 date "2002-10-15" @default.
• W2126359017 modified "2023-10-17" @default.
• W2126359017 title "New Perspectives on Atherogenesis" @default.
• W2126359017 cites W10435957 @default.
• W2126359017 cites W1510167055 @default.
• W2126359017 cites W1527680278 @default.
• W2126359017 cites W1817964822 @default.
• W2126359017 cites W1840979539 @default.
• W2126359017 cites W1879810571 @default.
• W2126359017 cites W1900613292 @default.
• W2126359017 cites W1967373175 @default.
• W2126359017 cites W1974805788 @default.
• W2126359017 cites W1977666051 @default.
• W2126359017 cites W1978339749 @default.
• W2126359017 cites W1983724939 @default.
• W2126359017 cites W1986340013 @default.
• W2126359017 cites W1987066539 @default.
• W2126359017 cites W1994148776 @default.
• W2126359017 cites W1996392591 @default.
• W2126359017 cites W1996611209 @default.
• W2126359017 cites W1998699321 @default.
• W2126359017 cites W1999361299 @default.
• W2126359017 cites W2013694272 @default.
• W2126359017 cites W2015776407 @default.
• W2126359017 cites W2018018443 @default.
• W2126359017 cites W2021976026 @default.
• W2126359017 cites W2029164903 @default.
• W2126359017 cites W2030610610 @default.
• W2126359017 cites W2031053394 @default.
• W2126359017 cites W2040171866 @default.
• W2126359017 cites W2041197131 @default.
• W2126359017 cites W2041307432 @default.
• W2126359017 cites W2051855777 @default.
• W2126359017 cites W2051870109 @default.
• W2126359017 cites W2056340128 @default.
• W2126359017 cites W2057271976 @default.
• W2126359017 cites W2059589608 @default.
• W2126359017 cites W2061014327 @default.
• W2126359017 cites W2067089828 @default.
• W2126359017 cites W2076809869 @default.
• W2126359017 cites W2083811960 @default.
• W2126359017 cites W2095150129 @default.
• W2126359017 cites W2095885613 @default.
• W2126359017 cites W2099378835 @default.
• W2126359017 cites W2100536144 @default.
• W2126359017 cites W2102783561 @default.
• W2126359017 cites W2113784056 @default.
• W2126359017 cites W2113973168 @default.
• W2126359017 cites W2114808162 @default.
• W2126359017 cites W2124100109 @default.
• W2126359017 cites W2126273261 @default.
• W2126359017 cites W2129741326 @default.
• W2126359017 cites W2129883875 @default.
• W2126359017 cites W2131037449 @default.
• W2126359017 cites W2135136607 @default.
• W2126359017 cites W2155846381 @default.
• W2126359017 cites W2157038552 @default.
• W2126359017 cites W2160942744 @default.
• W2126359017 cites W2188272555 @default.
• W2126359017 cites W2328529137 @default.
• W2126359017 cites W2334791394 @default.
• W2126359017 cites W2337035603 @default.
• W2126359017 cites W2403507619 @default.
• W2126359017 cites W4232807629 @default.
• W2126359017 cites W4252954747 @default.
• W2126359017 doi "https://doi.org/10.1161/01.cir.0000035280.64322.31" @default.
• W2126359017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12379586" @default.
• W2126359017 hasPublicationYear "2002" @default.
• W2126359017 type Work @default.
• W2126359017 sameAs 2126359017 @default.
• W2126359017 citedByCount "240" @default.
• W2126359017 countsByYear W21263590172012 @default.
• W2126359017 countsByYear W21263590172013 @default.
• W2126359017 countsByYear W21263590172014 @default.
• W2126359017 countsByYear W21263590172015 @default.
• W2126359017 countsByYear W21263590172016 @default.
• W2126359017 countsByYear W21263590172017 @default.
• W2126359017 countsByYear W21263590172018 @default.
• W2126359017 countsByYear W21263590172019 @default.
• W2126359017 countsByYear W21263590172020 @default.
• W2126359017 countsByYear W21263590172021 @default.
• W2126359017 countsByYear W21263590172022 @default.
• W2126359017 countsByYear W21263590172023 @default.
• W2126359017 crossrefType "journal-article" @default.
• W2126359017 hasAuthorship W2126359017A5007048045 @default.
• W2126359017 hasBestOaLocation W21263590171 @default.
• W2126359017 hasConcept C164705383 @default.
• W2126359017 hasConcept C177713679 @default.
• W2126359017 hasConcept C71924100 @default.
• W2126359017 hasConceptScore W2126359017C164705383 @default.
• W2126359017 hasConceptScore W2126359017C177713679 @default.
• W2126359017 hasConceptScore W2126359017C71924100 @default.
• W2126359017 hasIssue "16" @default.
• W2126359017 hasLocation W21263590171 @default.
• W2126359017 hasLocation W21263590172 @default.

• next